Tranquility Partners LLC Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Tranquility Partners LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 19.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 13,344 shares of the medical research company’s stock after selling 3,137 shares during the period. IQVIA accounts for approximately 1.0% of Tranquility Partners LLC’s portfolio, making the stock its 22nd biggest holding. Tranquility Partners LLC’s holdings in IQVIA were worth $2,622,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC purchased a new position in IQVIA in the 4th quarter valued at $1,616,000. Simplify Asset Management Inc. increased its stake in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Fifth Third Bancorp increased its position in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $197.64 on Thursday. The business has a 50 day simple moving average of $200.77 and a 200-day simple moving average of $218.81. The stock has a market capitalization of $35.87 billion, a PE ratio of 26.35, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

Insider Activity

In related news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IQV. Bank of America cut their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. UBS Group cut their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Finally, StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $251.67.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.